Global Cardiac Resynchronization Therapy (CRT) Devices Market 2015-2019
About Cardiac Resynchronization Therapy Devices
According to the WHO, cardiovascular disease is one of the leading cause of death worldwide. It is estimated that around 17.5 million people died from cardiovascular disease, which accounted for 31% of all global deaths in 2012. Cardiovascular disease can be prevented by addressing behavioral risks such as obesity, cigarette smoking, and an unhealthy diet.
CRT device is an implantable medical device that are used to resynchronize the contractions of the heart’s ventricles by sending tiny electrical impulses to the heart muscle, to pump the blood more efficiently.
Technavio's analysts forecast the global cardiac resynchronization therapy devices market to grow at a CAGR of 8.40% over the period 2014-2019.
Covered in this Report
The report includes the present scenario and the growth prospects of the global cardiac resynchronization therapy devices market for the period 2015-2019. The market can be segmented into two product: CRT-D devices and CRT-P devices.
Technavio's report, Global Cardiac Resynchronization Therapy Devices Market 2015-2019, has been prepared based on in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors.Key Regions
Technavio Announces the Publication of its Research Report – Global Cardiac Resynchronization Therapy (CRT) Devices Market 2015-2019
Technavio recognizes the following companies as the key players in the Global Cardiac Resynchronization Therapy (CRT) Devices Market: Boston Scientific, Medtronic and St. Jude Medical
Other Prominent Vendors in the market are: Biotronik, Cook Medical, Sorin Group and Spectranetics
Commenting on the report, an analyst from Technavio’s team said: “The CRT devices industry is focusing on developing innovative devices. The industry aims to minimize the manufacturing costs and materials used to provide efficient and useful devices that deliver tailored treatments to patients. For instance, Medtronic received FDA approval for its Viva CRT-D, which significantly improves the response rate for the treatment and provides economic benefits by reducing the number of hospitalizations.”
According to the report, according to WHO, cardiovascular diseases are the leading cause of death worldwide and accounted for 31% of all deaths in 2012. Stroke is also expected to be the second-leading cause of death in Europe by 2030, and it will be the primary cause of the increase in disability-adjusted years of life lost during the same period. Stroke and other cardiovascular diseases are expected to rise as the world's population ages. In addition, the increase in tobacco consumption and obesity are the major factors contributing to the rise in cardiovascular diseases. According to WHO, the prevalence of tobacco use is high in Europe. Therefore, a rise in the incidence of cardiovascular disease in Europe is expected to drive the market during the forecast period.
Further, the report states that as the increased acceptance of pacemakers and ICDs will hamper the growth of the market.
Boston Scientific, Medtronic, St. Jude Medical, Biotronik, Cook Medical, Sorin Group, Spectranetics